INCOG BioPharma
Private Company
Funding information not available
Overview
INCOG BioPharma is a US-based, private CDMO founded in 2016 that has rapidly established itself as a specialized player in the sterile injectable manufacturing space. The company's business model is purely service-based, providing comprehensive fill/finish solutions and leveraging a purpose-built, high-capacity facility designed for transparency and flexibility. With a focus on oncology and small molecule therapeutics from its clients, INCOG targets the growing market for outsourced manufacturing of complex injectables, competing on culture, client partnership, and operational excellence rather than a proprietary therapeutic pipeline.
Technology Platform
Purpose-built, FDA & Annex 1 compliant sterile injectable manufacturing facility featuring advanced fill/finish lines for multiple container types, robust analytical support, and device assembly/packaging. Emphasizes operational transparency through client viewing corridors and remote monitoring.
Opportunities
Risk Factors
Competitive Landscape
INCOG competes in the crowded injectable CDMO space against large global players (e.g., Catalent, Lonza, Baxter) and many niche specialists. Its competitive differentiation is based on a high-touch partnership model, a culture-focused 'Best Place to Work' environment, and a facility designed for maximum client transparency and collaboration.